サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1393002

連続バイオプロセスの世界市場：製品別、プロセス別、運用規模別、用途別、エンドユーザー別 - 予測（～2028年）

Continuous Bioprocessing Market by Product, Process, Scale of Operation, Application, & End User - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 263 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
連続バイオプロセスの世界市場：製品別、プロセス別、運用規模別、用途別、エンドユーザー別 - 予測（～2028年）
出版日: 2023年11月23日
発行: MarketsandMarkets
ページ情報: 英文 263 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

レポートの概要

調査範囲
調査対象年 2021年～2028年
基準年 2022年
予測期間 2023年～2028年
単位 100万米ドル
セグメント 製品、運用規模、プロセス、用途、エンドユーザー
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ

世界の連続バイオプロセスの市場規模は、2023年に2億1,800万米ドル、2028年までに5億9,900万米ドルに達し、2023年～2028年の予測期間にCAGRで22.4％の成長が予測されています。

市場の成長は、CDMOやCMOの連続バイオプロセスの採用増加に起因しています。連続バイオプロセスは、CDMOやCMOの間でバイオ医薬品の生産に向けて普及しつつあります。これらの組織は、バイオ医薬品をより速く、より効率的に製造するという圧力の増大に直面しており、連続バイオプロセスはこの需要に応えるのに役立ちます。さらに、連続バイオプロセスは、より大規模なプロジェクトや新たな治療領域へと移行しつつあります。この動向は、今後数年間の連続バイオプロセス市場の成長を促進すると予測されます。

「用途別では、モノクローナル抗体セグメントが2022年に最大のシェアを占めました。」

連続バイオプロセスは、モノクローナル抗体のバイオプロセスにおいて急速に勢いを増しており、小さな設備面積、低い投資コスト、柔軟性、プロセスの経済性といった潜在的な利点を提供しています。哺乳類細胞由来のモノクローナル抗体の商業的成功が、より高い生産性と柔軟性を提供し、コストを削減する新しいシングルユースバイオリアクターシステムに対する需要の増加につながっています。

「2023年～2028年の予測期間に米国が市場を独占し続けます。」

米国はバイオ医薬品の支配的な市場であり、世界市場の約3分の1を占めています。バイオ医薬品研究開発の世界的リーダーでもあります。米国研究製薬工業協会（PhRMA）によると、米国の製薬企業はほとんどの新薬の知的財産権を保有しており、世界の医薬品研究開発の半分以上を実施しています。米国のバイオプロセス企業は、連続バイオプロセスを用いたバイオ医薬品の開発に積極的に参加しています。またこれらの企業は、ターンアラウンドタイムが短く、エネルギー効率の高い灌流ベースの製品を広く提供しています。これらの要因が、同国の連続バイオプロセス市場の成長を支えています。

当レポートでは、世界の連続バイオプロセス市場について調査分析し、主な促進要因と抑制要因、競合情勢、将来の動向などの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 連続バイオプロセス市場の概要
  • 北米の連続バイオプロセス市場：製品別
  • 連続バイオプロセス市場：用途別
  • 連続バイオプロセス市場：地理的な成長機会

第5章 市場の概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 価格分析
  • 顧客のビジネスに影響を与える動向/混乱
  • バリューチェーン分析
    • 研究・製品開発
    • 原材料、製造、組立
    • 販売、アフターサービス
  • サプライチェーン分析
  • エコシステム分析
  • 特許分析
  • 主な会議とイベント
  • 規制情勢
    • 規制機関、政府機関、その他の組織
    • 規制ガイドライン
  • ポーターのファイブフォース分析
  • 技術分析
  • 主なステークホルダーと購入基準
  • 主な購入基準：エンドユーザー別

第6章 連続バイオプロセス市場：製品別

  • イントロダクション
  • クロマトグラフィシステム、消耗品
  • ろ過システム、装置
  • バイオリアクター
  • 細胞培養培地、細胞株、バッファー、試薬
  • その他の製品

第7章 連続バイオプロセス市場：運用規模別

  • イントロダクション
  • 商業運用
  • 臨床運用

第8章 連続バイオプロセス市場：プロセス別

  • イントロダクション
  • 下流バイオプロセス
  • 上流バイオプロセス

第9章 連続バイオプロセス市場：用途別

  • イントロダクション
  • モノクローナル抗体
  • ワクチン
  • 細胞・遺伝子治療
  • その他の用途

第10章 連続バイオプロセス市場：エンドユーザー別

  • イントロダクション
  • 製薬企業、バイオテクノロジー企業
  • 開発業務受託機関（CRO）、製造受託機関（CMO）
  • 学術・研究機関

第11章 連続バイオプロセス市場：地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • 北米の不況の影響
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
    • 欧州の不況の影響
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • その他のアジア太平洋
    • アジア太平洋の不況の影響
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他のラテンアメリカ
    • ラテンアメリカの不況の影響
  • 中東・アフリカ
    • 中東
    • アフリカ
    • 中東・アフリカの不況の影響

第12章 競合情勢

  • 概要
  • 主要企業戦略/有力企業
  • 収益シェア分析
  • 市場シェア分析
  • 企業の評価マトリクス
  • スタートアップ/中小企業の評価マトリクス
  • 競合シナリオと動向

第13章 企業プロファイル

  • 主要企業
    • DANAHER CORPORATION
    • SARTORIUS AG
    • THERMO FISHER SCIENTIFIC INC.
    • REPLIGEN CORPORATION
    • MERCK KGAA
    • 3M COMPANY
    • GETINGE AB
    • EPPENDORF SE
    • CORNING INCORPORATED
    • ENTEGRIS
    • FUJIFILM HOLDINGS CORPORATION
    • MEISSNER FILTRATION PRODUCTS, INC.
    • KUHNER AG
    • ESCO LIFESCIENCES GROUP
    • SATAKE MULTIMIX CORPORATION
  • その他の企業
    • BIONET
    • STOBBE GROUP
    • BBI-BIOTECH GMBH
    • OMNIBRX BIOTECHNOLOGIES
    • CELL CULTURE COMPANY, LLC
    • PIERRE GUERIN
    • SOLIDA BIOTECH GMBH
    • ZELLWERK GMBH
    • 3D BIOTEK, LLC
    • FIBERCELL SYSTEMS INC.

第14章 付録

目次
Product Code: PH 8866

Report Description

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Million
SegmentsProduct, Scale of Operation, Process, Application & End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

The global continuous bioprocessing market is projected to reach USD 599 million by 2028 from USD 218 million in 2023, at a CAGR of 22.4% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing adoption of continuous bioprocessing among CDMOs and CMOs. Continuous bioprocessing is becoming more popular among CDMOs and CMOs for the production of biopharmaceuticals. These organizations face increasing pressure to manufacture biopharmaceuticals faster and more efficiently, and continuous bioprocessing can help them meet this demand. Additionally, continuous bioprocessing is moving into larger-scale projects and new therapeutic areas. This trend is expected to drive the growth of the continuous bioprocessing market in the coming years.

"The monoclonal antibodies segment accounted for the largest share by application in 2022."

In 2022, the monoclonal antibodies segment accounted for the largest share by application in the global continuous bioprocessing market. Continuous bioprocessing is rapidly gaining momentum in monoclonal antibody bioprocessing, providing potential advantages such as smaller facility footprints, lower investment costs, flexibility, and process economy. The commercial success of mammalian cell-derived mAbs has led to the increased demand for novel single-use bioreactor systems that provide greater productivity & flexibility and reduce costs.

"The US has continued to dominate the continuous bioprocessing market during the forecast period of 2023-2028."

The US dominated the continuous bioprocessing market in North America in 2022. The US is the dominant market for biopharmaceuticals, accounting for around a third of the global market. It is the world leader in biopharmaceutical R&D. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), US pharmaceutical firms hold the intellectual property rights for most new medicines and conduct over half the world's R&D in pharmaceuticals. Bioprocessing companies in the US are actively participating in the development of biopharmaceuticals using continuous bioprocessing. These companies are also widely offer perfusion-based products, which offer less turnaround time and are energy-efficient. These factors are supporting the growth of the continuous bioprocessing market in the country.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

  • Thermo Fisher Scientific Inc. (US)
  • Danaher Corporation (US)
  • Sartorius AG (Germany)
  • Thermo Fisher Scientific Inc. (US)
  • Repligen Corporation (US)
  • Merck KGaA (Germany)
  • 3M Company (US)
  • Getinge AB (Sweden)
  • Eppendorf SE (Germany)
  • Corning Incorporated (US)
  • Entegris (US)
  • FUJIFILM Holdings Corporation (Japan)
  • Meissner filtration products, Inc. (US)
  • Kuhner AG (Switzerland)
  • Esco Lifesciences Group (Singapore)
  • SATAKE MultiMix Corporation (Japan)
  • Bionet (Spain)
  • Stobbe Group (Switzerland)
  • bbi-biotech GmbH (Germany)
  • OmniBRx Biotechnologies (India)
  • Cell Culture Company, LLC (US)
  • Pierre Guerin (France)
  • Solida Biotech GmbH (Germany)
  • Zellwerk GmbH (Germany)
  • 3D Biotek, LLC (US)
  • FiberCell Systems Inc. (US)

Research Coverage:

This research report categorizes the continuous bioprocessing market by product (chromatography systems and consumables, filtration systems and devices, bioreactors, cell culture media, cell lines, buffers and reagents, and other products), by scale of operation (commercial operations and clinical operations), by process (downstream bioprocess and upstream bioprocess), by application (monoclonal antibodies, vaccines, cell and gene therapy, and other applications), by end users (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs) & contract manufacturing organizations (CMOs), and academic & research institutes) and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the continuous bioprocessing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the continuous bioprocessing market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall continuous bioprocessing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising demand for biopharmaceuticals, growing adoption among CDMOs and CMOs, advantages of continuous bioprocessing over batch/fed-batch mode, favorable regulatory & government support for innovative technologies, and emergence of integrated end-to-end continuous bioprocessing), restraints (high capital investment to limit entry for small players and stringent regulatory requirements), opportunities (high growth potential of emerging economies and PAT-enabled optimization of continuous bioprocessing), and Challenges (integration into existing manufacturing facilities and operational challenges) influencing the growth of the market.
  • Product Development/Innovation: Detailed insights on newly launched products of the continuous bioprocessing market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the continuous bioprocessing market
  • Competitive Assessment: Danaher Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), Repligen Corporation (US), Merck KGaA (Germany), 3M Company (US), Getinge AB (Sweden), Eppendorf SE (Germany), Corning Incorporated (US), Entegris (US), FUJIFILM Holdings Corporation (Japan), Meissner filtration products, Inc. (US), Kuhner AG (Switzerland), Esco Lifesciences Group (Singapore), SATAKE MultiMix Corporation (Japan), and among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SEGMENTATION
    • FIGURE 1 CONTINUOUS BIOPROCESSING MARKET SEGMENTATION
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 LIMITATIONS
  • 1.7 STAKEHOLDERS
  • 1.8 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 CONTINUOUS BIOPROCESSING MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022)
    • FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS)
    • FIGURE 6 ILLUSTRATIVE EXAMPLE OF SARTORIUS AG: REVENUE SHARE ANALYSIS (2022)
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
    • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH FORECAST
    • FIGURE 9 CONTINUOUS BIOPROCESSING MARKET: CAGR PROJECTIONS (2023-2028)
    • FIGURE 10 CONTINUOUS BIOPROCESSING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.4 DATA TRIANGULATION & MARKET BREAKDOWN
    • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2030 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 12 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 17 GEOGRAPHICAL SNAPSHOT OF CONTINUOUS BIOPROCESSING MARKET

4 PREMIUM INSIGHTS

  • 4.1 CONTINUOUS BIOPROCESSING MARKET OVERVIEW
    • FIGURE 18 RISING DEMAND FOR BIOPHARMACEUTICALS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
  • 4.2 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT
    • FIGURE 19 CHROMATOGRAPHY SYSTEMS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.3 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION
    • FIGURE 20 MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.4 CONTINUOUS BIOPROCESSING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
    • FIGURE 22 CONTINUOUS BIOPROCESSING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.2 MARKET DYNAMICS
    • TABLE 4 CONTINUOUS BIOPROCESSING MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising demand for biopharmaceuticals
      • 5.2.1.2 Growing adoption among CDMOs and CMOs
      • 5.2.1.3 Advantages of continuous bioprocessing over batch/fed-batch mode
      • 5.2.1.4 Favorable regulatory & government support for innovative technologies
      • 5.2.1.5 Emergence of integrated end-to-end continuous bioprocessing
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High capital investments to limit entry for smaller players
      • 5.2.2.2 Stringent regulatory requirements
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High growth potential of emerging economies
      • 5.2.3.2 PAT-enabled optimization of continuous bioprocessing
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Integration into existing manufacturing facilities
      • 5.2.4.2 Operational challenges
  • 5.3 PRICING ANALYSIS
    • TABLE 5 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY KEY PLAYER (2022)
    • TABLE 6 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY REGION (2022)
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 23 REVENUE SHIFT AND NEW POCKETS FOR CONTINUOUS BIOPROCESSING PRODUCT PROVIDERS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 24 CONTINUOUS BIOPROCESSING MARKET: VALUE CHAIN ANALYSIS
    • 5.5.1 RESEARCH & PRODUCT DEVELOPMENT
    • 5.5.2 RAW MATERIAL, MANUFACTURING, AND ASSEMBLY
    • 5.5.3 DISTRIBUTION AND AFTER-SALES SERVICES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 25 CONTINUOUS BIOPROCESSING MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 26 ECOSYSTEM MARKET MAP: CONTINUOUS BIOPROCESSING MARKET
    • TABLE 7 CONTINUOUS BIOPROCESSING MARKET: ROLE IN ECOSYSTEM (SUPPLY/DEMAND SIDE)
  • 5.8 PATENT ANALYSIS
    • FIGURE 27 PATENT APPLICATIONS FOR CONTINUOUS BIOPROCESSING MARKET (JANUARY 2013-SEPTEMBER 2023)
  • 5.9 KEY CONFERENCES AND EVENTS
    • TABLE 8 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023-2024)
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.2 REGULATORY GUIDELINES
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 13 CONTINUOUS BIOPROCESSING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF SUPPLIERS
    • 5.11.4 BARGAINING POWER OF BUYERS
    • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12 TECHNOLOGY ANALYSIS
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS BIOPROCESSING PRODUCTS
  • 5.14 KEY BUYING CRITERIA, BY END USER
    • FIGURE 29 KEY BUYING CRITERIA OF END USERS IN CONTINUOUS BIOPROCESSING MARKET

6 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 14 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES
    • 6.2.1 ADVANTAGES OF HIGH PRODUCTIVITY AND AFFORDABILITY TO DRIVE MARKET
    • TABLE 15 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 16 NORTH AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 17 EUROPE: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 18 ASIA PACIFIC: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 19 LATIN AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 20 MIDDLE EAST & AFRICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 FILTRATION SYSTEMS AND DEVICES
    • 6.3.1 RISING TECHNOLOGICAL ADVANCEMENTS IN FILTRATION SYSTEMS TO DRIVE MARKET
    • TABLE 21 FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 22 NORTH AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 EUROPE: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 ASIA PACIFIC: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 LATIN AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 MIDDLE EAST & AFRICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 BIOREACTORS
    • 6.4.1 ABILITY TO ENABLE PROCESS INTENSIFICATION TO BOOST DEMAND
    • TABLE 27 BIOREACTORS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 28 NORTH AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 29 EUROPE: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 ASIA PACIFIC: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 LATIN AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 MIDDLE EAST & AFRICA: BIOREACTORS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.5 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS
    • 6.5.1 INNOVATIONS IN CELL LINE DEVELOPMENT TO SUPPORT MARKET GROWTH
    • TABLE 33 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 34 NORTH AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 35 EUROPE: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 ASIA PACIFIC: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 LATIN AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 MIDDLE EAST & AFRICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.6 OTHER PRODUCTS
    • TABLE 39 OTHER PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 40 NORTH AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 41 EUROPE: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 LATIN AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 44 MIDDLE EAST & AFRICA: OTHER PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)

7 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION

  • 7.1 INTRODUCTION
    • TABLE 45 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
  • 7.2 COMMERCIAL OPERATIONS
    • 7.2.1 GROWING FOCUS ON COST-REDUCTION OF BIOSIMILARS TO PROPEL MARKET
    • TABLE 46 CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 47 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 50 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 CLINICAL OPERATIONS
    • 7.3.1 INNOVATIONS IN R&D TESTING FOR THERAPEUTIC EFFICACY TO DRIVE MARKET
    • TABLE 52 CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 53 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 56 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 57 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)

8 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS

  • 8.1 INTRODUCTION
    • TABLE 58 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
  • 8.2 DOWNSTREAM BIOPROCESS
    • 8.2.1 RISING TECHNOLOGICAL ADVANCEMENTS SUCH AS SPTFF AND MULTICOLUMN CHROMATOGRAPHY TO PROPEL MARKET
    • TABLE 59 CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 61 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 62 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 UPSTREAM BIOPROCESS
    • 8.3.1 ADOPTION OF PERFUSION TECHNOLOGY TO SUPPORT MARKET GROWTH
    • TABLE 65 CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 66 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 67 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 69 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION)

9 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 71 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 9.2 MONOCLONAL ANTIBODIES
    • 9.2.1 GROWING FOCUS ON THERAPEUTIC APPLICATIONS TO PROPEL MARKET
    • TABLE 72 CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 73 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 75 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 76 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 77 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 VACCINES
    • 9.3.1 USE OF PERFUSION BIOREACTORS FOR VACCINE PRODUCTION TO DRIVE MARKET
    • TABLE 78 CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 79 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 82 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 83 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION)
  • 9.4 CELL & GENE THERAPY
    • 9.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO BOOST DEMAND
    • TABLE 84 CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 85 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 86 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 87 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 88 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION)
  • 9.5 OTHER APPLICATIONS
    • TABLE 90 CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 91 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 92 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 93 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 94 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 95 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

10 CONTINUOUS BIOPROCESSING MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 96 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.2.1 RISING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET
    • TABLE 97 CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 98 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 99 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 101 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 102 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
  • 10.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) AND CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
    • 10.3.1 RISING OUTSOURCING OF R&D SERVICES BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO PROPEL MARKET
    • TABLE 103 CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 104 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 106 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 107 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 108 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)
  • 10.4 ACADEMIC & RESEARCH INSTITUTES
    • 10.4.1 COLLABORATIONS BETWEEN PHARMACEUTICAL MANUFACTURERS AND RESEARCH INSTITUTES TO SUPPORT MARKET GROWTH
    • TABLE 109 CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 110 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 111 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 112 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 113 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 114 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)

11 CONTINUOUS BIOPROCESSING MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 115 CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 30 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT
    • TABLE 116 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 117 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 118 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 119 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 120 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 121 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 High biopharmaceutical R&D spending to drive market
    • TABLE 122 US: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 123 US: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 124 US: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 125 US: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 126 US: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Growing establishment of biopharmaceutical manufacturing facilities to propel market
    • TABLE 127 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 128 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 129 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 130 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 131 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.3 NORTH AMERICA: RECESSION IMPACT
  • 11.3 EUROPE
    • TABLE 132 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 133 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 134 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 135 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 136 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 137 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Increasing initiatives for life sciences research to boost demand
    • TABLE 138 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 139 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 140 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 141 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 142 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.2 UK
      • 11.3.2.1 Favorable government support for biotech clusters to propel market
    • TABLE 143 UK: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 144 UK: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 145 UK: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 146 UK: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 147 UK: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.3 FRANCE
      • 11.3.3.1 Rising demand for mAbs and biologics to drive market
    • TABLE 148 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 149 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 150 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 151 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 152 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Growth in pharma & biopharma industries to boost demand
    • TABLE 153 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 154 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 155 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 156 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 157 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 Increasing R&D funding by academic institutes to support market growth
    • TABLE 158 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 159 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 160 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 161 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 162 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.6 REST OF EUROPE
    • TABLE 163 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 164 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 165 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 166 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 167 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.7 EUROPE: RECESSION IMPACT
  • 11.4 ASIA PACIFIC
    • FIGURE 31 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT
    • TABLE 168 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 169 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 170 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 171 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 172 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 173 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 Government support and rising private investments to drive market growth
    • TABLE 174 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 175 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 176 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 177 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 178 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Stringent regulatory guidelines for pharmaceutical drug safety to support market growth
    • TABLE 179 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 180 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 181 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 182 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 183 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Growth in pharmaceutical industry to boost demand
    • TABLE 184 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 185 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 186 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 187 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 188 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.4 SOUTH KOREA
      • 11.4.4.1 Rising focus on quality manufacturing practices to drive market
    • TABLE 189 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 190 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 191 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 192 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 193 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.5 REST OF ASIA PACIFIC
    • TABLE 194 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 195 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 196 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 197 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 198 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.6 ASIA PACIFIC: RECESSION IMPACT
  • 11.5 LATIN AMERICA
    • TABLE 199 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 200 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 201 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 202 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 203 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 204 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.1 BRAZIL
      • 11.5.1.1 Rising focus on cell & therapy manufacturing to support market
    • TABLE 205 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 206 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 207 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 208 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 209 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.2 MEXICO
      • 11.5.2.1 Increasing expansion of pharmaceutical companies to support market growth
    • TABLE 210 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 211 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 212 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 213 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 214 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.3 REST OF LATIN AMERICA
    • TABLE 215 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 216 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 217 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 218 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 219 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.4 LATIN AMERICA: RECESSION IMPACT
  • 11.6 MIDDLE EAST & AFRICA
    • TABLE 220 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 221 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 222 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 223 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 224 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 225 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.6.1 MIDDLE EAST
      • 11.6.1.1 Increasing demand for biopharmaceutical drugs to drive market
    • TABLE 226 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 227 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 228 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 229 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 230 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.6.2 AFRICA
      • 11.6.2.1 Favorable initiatives for R&D investments to support market growth
    • TABLE 231 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 232 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 233 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 234 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 235 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.3 REVENUE SHARE ANALYSIS
    • FIGURE 32 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2018-2022)
  • 12.4 MARKET SHARE ANALYSIS
    • FIGURE 33 CONTINUOUS BIOPROCESSING MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
    • TABLE 236 CONTINUOUS BIOPROCESSING MARKET: INTENSITY OF COMPETITIVE RIVALRY
  • 12.5 COMPANY EVALUATION MATRIX
    • 12.5.1 STARS
    • 12.5.2 PERVASIVE PLAYERS
    • 12.5.3 EMERGING LEADERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 34 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
    • 12.5.5 COMPANY FOOTPRINT ANALYSIS
    • TABLE 237 CONTINUOUS BIOPROCESSING MARKET: OVERALL COMPANY FOOTPRINT (2022)
    • 12.5.6 PRODUCT FOOTPRINT OF COMPANIES
    • TABLE 238 CONTINUOUS BIOPROCESSING MARKET: PRODUCT FOOTPRINT ANALYSIS
    • 12.5.7 REGIONAL FOOTPRINT OF COMPANIES
    • TABLE 239 CONTINUOUS BIOPROCESSING MARKET: REGIONAL FOOTPRINT ANALYSIS
  • 12.6 START-UP/SME EVALUATION MATRIX
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • FIGURE 35 COMPANY EVALUATION MATRIX FOR START-UP/SMES (2022)
    • 12.6.5 COMPETITIVE BENCHMARKING OF START-UP/SMES
    • TABLE 240 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
    • TABLE 241 CONTINUOUS BIOPROCESSING MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
  • 12.7 COMPETITIVE SCENARIOS AND TRENDS
    • 12.7.1 PRODUCT LAUNCHES
    • TABLE 242 CONTINUOUS BIOPROCESSING MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-OCTOBER 2023)
    • 12.7.2 DEALS
    • TABLE 243 CONTINUOUS BIOPROCESSING MARKET: DEALS (JANUARY 2020-OCTOBER 2023)
    • 12.7.3 OTHER DEVELOPMENTS
    • TABLE 244 CONTINUOUS BIOPROCESSING MARKET: OTHER DEVELOPMENTS (JANUARY 2020-OCTOBER 2023)

13 COMPANY PROFILES

  • (Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)**
  • 13.1 KEY PLAYERS
    • 13.1.1 DANAHER CORPORATION
    • TABLE 245 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 36 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
    • 13.1.2 SARTORIUS AG
    • TABLE 246 SARTORIUS AG: BUSINESS OVERVIEW
    • FIGURE 37 SARTORIUS AG: COMPANY SNAPSHOT (2022)
    • 13.1.3 THERMO FISHER SCIENTIFIC INC.
    • TABLE 247 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • 13.1.4 REPLIGEN CORPORATION
    • TABLE 248 REPLIGEN CORPORATION: BUSINESS OVERVIEW
    • FIGURE 39 REPLIGEN CORPORATION: COMPANY SNAPSHOT (2022)
    • 13.1.5 MERCK KGAA
    • TABLE 249 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 13.1.6 3M COMPANY
    • TABLE 250 3M COMPANY: BUSINESS OVERVIEW
    • FIGURE 41 3M COMPANY: COMPANY SNAPSHOT (2022)
    • 13.1.7 GETINGE AB
    • TABLE 251 GETINGE AB: BUSINESS OVERVIEW
    • FIGURE 42 GETINGE AB: COMPANY SNAPSHOT (2022)
    • 13.1.8 EPPENDORF SE
    • TABLE 252 EPPENDORF SE: BUSINESS OVERVIEW
    • FIGURE 43 EPPENDORF SE: COMPANY SNAPSHOT (2022)
    • 13.1.9 CORNING INCORPORATED
    • TABLE 253 CORNING INCORPORATED: BUSINESS OVERVIEW
    • FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)
    • 13.1.10 ENTEGRIS
    • TABLE 254 ENTEGRIS: BUSINESS OVERVIEW
    • FIGURE 45 ENTEGRIS: COMPANY SNAPSHOT (2022)
    • 13.1.11 FUJIFILM HOLDINGS CORPORATION
    • TABLE 255 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 46 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
    • 13.1.12 MEISSNER FILTRATION PRODUCTS, INC.
    • TABLE 256 MEISSNER FILTRATION PRODUCTS, INC.: BUSINESS OVERVIEW
    • 13.1.13 KUHNER AG
    • TABLE 257 KUHNER AG: BUSINESS OVERVIEW
    • 13.1.14 ESCO LIFESCIENCES GROUP
    • TABLE 258 ESCO LIFESCIENCES GROUP: BUSINESS OVERVIEW
    • 13.1.15 SATAKE MULTIMIX CORPORATION
    • TABLE 259 SATAKE MULTIMIX CORPORATION: BUSINESS OVERVIEW
  • 13.2 OTHER PLAYERS
    • 13.2.1 BIONET
    • 13.2.2 STOBBE GROUP
    • 13.2.3 BBI-BIOTECH GMBH
    • 13.2.4 OMNIBRX BIOTECHNOLOGIES
    • 13.2.5 CELL CULTURE COMPANY, LLC
    • 13.2.6 PIERRE GUERIN
    • 13.2.7 SOLIDA BIOTECH GMBH
    • 13.2.8 ZELLWERK GMBH
    • 13.2.9 3D BIOTEK, LLC
    • 13.2.10 FIBERCELL SYSTEMS INC.
  • *Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)** might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS